Clinical trials: Women Diagnosed With Cancer
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Cervical Cancer
High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies.
This phase II study of high dose intensity modulated radiation therapy in the cervical cancer with metastatic lymphadenopathies at initial diagnosis
- Trial name
- NCT01730651
- Testing
- Tomotherapy
- Where
- 2 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- National Cancer Center, Korea
Hepatitis C, Breast Cancer
Hepatitis C Screening Paired With Mammography
In France, a breast cancer screening is organized since 2004 for women aged 50-74. On the other hand, even though the seroprevalence of hepatitis C in the general French population is less than 1%, it is estimated that more than…
- Trial name
- Mammo'C (NCT05067374)
- Where
- 4 sites in France
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Bladder Cancer, Quality of Life
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
Among bladder cancer, the majority of them (70%) are non-muscle-invasive bladder cancer (NMIBC). The survival time is even longer in NMIBC. Patients with NMIBC receive surgery or transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT05739968
- Testing
- Usual care + oncology case manager (OCM) care, Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Polycystic Ovary Syndrome, Diet Habit
The Results of the Mediterranean Diet for PCOS
The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month in patients with a body mass index of 25 and more who were followed up in our clinic due…
- Trial name
- PCOS (NCT06442189)
- Testing
- Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital
Breast Neoplasm Female, Nutrition Related Cancer
Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women
Breast cancer is the most frequent tumor in Western women. In Spain about 26,000 new breast cancers are diagnosed each year. This type of tumor is increasing worldwide with an increase in aggressive neoplasms in young women.
- Conditions
- Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast
- Trial name
- Mamanut (NCT03918668)
- Testing
- Women with recent diagnosis of breast cancer
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Ovarian Neoplasms
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO).
- Trial name
- NCT07694427
- Testing
- Mocertatug rezetecan, Bevacizumab
- Where
- 12 sites in Argentina, Australia and 3 more
- Volunteers
- 720 people
- Sponsor
- GlaxoSmithKline
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2…
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma
- Trial name
- NCT02466971
- Testing
- Brachytherapy, Cisplatin, External Beam Radiation Therapy
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
To assess the effects of short term administration of celecoxib 400 mg bid between biopsy and reexcision.
- Trial name
- NCT00328432
- Testing
- celecoxib 400 mg bid
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Ovarian Cancer
Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal
BOVARY-CE is a monocentric, pilot, longitudinal, real-life study with a total duration of 36 months. The purpose of this study is to assess the feasibility of using liquid biopsy as a substitute for tissue multisampling, in order…
- Trial name
- BOVARY CE (NCT04511988)
- Testing
- Diagnostic Test
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut de Cancérologie de Lorraine
Bladder Cancer
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
The goal of this clinical trial is to see if a new designed optical coherence tomography catheter can be used in bladder cancer in patients undergoing a transurethral resection of a bladder tumour.
- Trial name
- BLOCT (NCT06679920)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Amsterdam UMC
Breast Neoplasm
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
The purpose of this study is to determine whether a multimodal program based on therapeutic exercise and vagal activation techniques for newly diagnosed breast cancer women has better results in terms of neurotoxicity prevenion…
- Trial name
- ATENTO (NCT04583124)
- Testing
- ATENTO-B, ATENTO-T
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Universidad de Granada
Ovarian Cancer
Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants
The purpose of this study is to try and understand if there is added benefit or increased harm when antioxidant nutritional supplements are added to traditional chemotherapy in the treatment of ovarian cancer.
- Trial name
- NCT00228319
- Testing
- Oral Ascorbic Acid, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Jeanne Drisko, MD, CNS, FACN
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancers
Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
The goal of this prospective, single-arm feasibility study is to evaluate the safety and feasibility of using Gleolan® (5-aminolevulinic acid), an FDA-approved drug currently used during brain tumor surgery, in adults with…
- Trial name
- NCT07828704
- Testing
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Henry Ford Health System
Ovarian Cancer, Epithelial
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology.
- Trial name
- NCT06640348
- Testing
- No intervention
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Ovarian Cancer
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly…
- Trial name
- NCT06437353
- Testing
- Paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Anhui Provincial Cancer Hospital